Efficacy and safety of lanadelumab for prophylactic treatment in adolescents with hereditary angioedema (HAE)

      The efficacy and safety of lanadelumab, a monoclonal antibody targeting plasma kallikrein, in adolescents with HAE with C1-inhibitor deficiency (HAE-C1-INH) were investigated in a phase 3 trial and its open-label extension.
      To read this article in full you will need to make a payment